Variation in individual response to statin therapy has been widely studied for a potential genetic component. Multiple genes have been identified as potential modulators of statin response, but few study findings have replicated. To further examine these associations, 2735 individuals on statin therapy, half on atorvastatin and the other half divided among fluvastatin, lovastatin, pravastatin and simvastatin were genotyped for 43 SNPs in 16 genes that have been implicated in statin response. Associations with lowdensity lipoprotein cholesterol (LDL-C) lowering, total cholesterol lowering, HDL-C elevation and triglyceride lowering were examined. The only significant associations with LDL-C lowering were found with apoE2 in which carriers of the rare allele who took atorvastatin lowered their LDL-C by 3.5% more than those homozygous for the common allele and with rs2032582 (S893A in ABCB1) in which the two groups of homozygotes differed by 3% in LDL-C lowering. These genetic effects were smaller than those observed with the demographic variables of age and gender. The magnitude of all the differences found is sufficiently small that genetic data from these genes should not influence clinical decisions on statin administration.
INTRODUCTION
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), known as statins, have been used clinically for lowering low-density lipoprotein cholesterol (LDL-C) for more than a decade. Most patients taking these drugs respond favorably to them with substantial reductions in LDL-C. 1 Despite the generally good response to statins, some variation in response has been noted and the causes have been subject to a variety of investigations. Potential causes for the variation include compliance with taking the medication 2 as well as variation in the genes 3, 4 involved in either the cholesterol/lipid pathways or uptake/metabolism of statins.
Significant efforts have been expended on determining whether variation in statin response arises from identifiable genetic differences. 3, 4 Initially, the LDL receptor gene was the primary target of study, but later efforts have included most genes involved in lipoprotein metabolism as well as others involved in statin pharmacokinetics. Studies have varied considerably in size and have included all statins on the market. The large number of positive studies found in the literature suggests that many genes could affect statin efficacy. However, the infrequent replication and the small size of some studies cause concern that publication bias and random variation may also play a role in the reported positive results.
In one review, 4 associations of genotype with statin response results were summarized from 22 studies covering more than 20 genes. While nine different genes were noted to be significantly associated with LDL-C lowering caused by statins, only apoE was identified in more than one study and nearly as many studies with apoE were negative as were positive. Among the positive studies with other genes, the number of patients was as low as 47 and only one study examined more than 400 individuals. The largest study 5 examined pravastatin with 1536 patients for 148 SNPs across 10 genes and found that only two highly linked SNPs in the HMGCR gene were associated with pravastatin response. To determine whether associations reported in the literature with any statin could be replicated, we genotyped 2735 individuals for 43 SNPs in 16 genes chosen based on literature studies.
RESULTS
SNPs were chosen for genotyping based on a survey of the literature for genetic associations with statin response. Medline and Current Contents were searched for articles with keywords statin, Lipitor or HMGCR and combined with keywords SNP, polymorphism, genotype or genetic. The resultant articles and their bibliographies were then used to identify relevant studies. While most SNPs that we genotyped were identical to those in the original reports, two SNPs in the ACE gene were analyzed instead of the insertion/ deletion polymorphism due to the technically easier assays. Both SNPs are in high linkage disequilibrium with the insertion/deletion polymorphism 6, 7 and were greater than 99% concordant with each other. All SNPs were in HardyWeinberg equilibrium with P40.05 except for rs7412 (Table 1) . For this SNP, the deviation (P ¼ 0.03) was not significant after correction for multiple testing.
In the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS), 8 approximately half of the 3916 subjects were administered atorvastatin, while the remainder was divided among fluvastatin, lovastatin, pravastatin and simvastatin. In all, 70% of these individuals consented to DNA analysis. For the primary study goal, patients were re-examined 6 weeks after the start of therapy to determine whether LDL-C goals had been reached. Compliance with therapy for the different statins ranged from 93.5 to 95.2% as determined by return of pill bottles and counting of remaining pills at 6 weeks. To determine whether any SNPs might be associated with the statin response, primary end points (absolute or percentage changes from the baseline in LDL-C, total cholesterol, triglyceride and HDL-C at 6 weeks after the start of therapy) were examined as a function of genotype. The genotype effect of each polymorphism was evaluated using analysis of covariance (ANCOVA) for each statin.
The most significant associations with Caucasians (89% of all subjects) for percentage changes in LDL-C, HDL-C, triglycerides and total cholesterol are shown in Table 2 and all the P-values listed are uncorrected for multiple testing. For percent changes, all phenotypes with any statin and a genetic association with Po0.01 are shown. Some SNPs were not included in the association analysis because their low frequency prevented useful conclusions from being drawn.
When percent LDL-C lowering by atorvastatin is examined as a function of genotype in Caucasians, the most significant associations were found with rs7412, the polymorphism responsible for the apoE2 protein and rs2032582 in ABC B1. Caucasians heterozygous for the rare allele of rs7412 have a 39.9% lowering of LDL-C compared to a 36.4% lowering among Caucasians with the common allele (P ¼ 0.0015). Analysis of apoE using haplotypes rather than the individual SNPs did not increase the significance of the result. A similar but less pronounced effect was seen with rs2032582 in which individuals homozygous for S893 have LDL-C lowering of 3% less than those homozygous for A893. Those heterozygous at this position have an intermediate LDL-C lowering. Another ABC B1 SNP, rs1045642, was less significantly associated with LDL-C lowering (P ¼ 0.02, 2.3% difference between heterozygotes and those homozygous for the common allele).
rs4149036 in OATP-C is associated with triglyceride lowering (P ¼ 0.0024), but only among those homozygous for the rare allele (4.3% of this group). This is similar to the less significant effects of OATP-C SNPs rs4149080 (P ¼ 0.026) and rs4149056 (P ¼ 0.037) on HDL-C in which only those homozygous for the rare allele show an apparent effect (2.5 and 1.6% of these groups, respectively). The only other SNP with Po0.01 with atorvastatin is rs776746 in CYP3A5 (P ¼ 0.0024). However, with this SNP, the largest LDL-C lowering is found with the heterozygous individuals and lesser effects are found with both sets of homozygotes, raising the possibility that this association is spurious. The same effect was found among TaqIB (CETP) heterozygotes (P ¼ 0.036), also suggesting a spurious association. The same SNPs and similar associations were found when absolute rather than percent LDL-C lowering was examined. For percent total cholesterol lowering, only rs2032582 (P ¼ 0.008) and rs7412 (P ¼ 0.03) were significant. For triglyceride lowering and HDL-C elevation, the only SNP beyond those mentioned above with Po0.05 was rs2740574 in CYP3A4 (P ¼ 0.03).
When the results for Caucasians with all other statins are examined, the most significant effect is seen with a hepatic lipase SNP (rs1800588) that is associated with the HDL-C response to fluvastatin (P ¼ 0.001). The effect with HDL-C trends in a uniform direction with heterozygous individuals intermediate between the two homozygous states. A similar effect was seen for the same SNP and simvastatin. Heterozygotes and homozygotes with the rare allele showed the same difference as fluvastatin, but individuals with two common alleles did not show the same pattern. As with atorvastatin, SNPs in OATP-C showed association with HDL-C and triglyceride effects with lovastatin and fluvastatin. The genes and SNPs examined are listed in columns 1 and 2 with dbSNP identifiers, if available. The location of each SNP in the May 2004 genome assembly is provided in columns 3 and 4. If the SNP is commonly referred to by another name or is in the coding sequence, alternate names are provided in column 5. Columns 6-9 contain the allele frequency for a given SNP for Asians, African Americans (Af. Am.), Caucasians (Cauc.) and Hispanics (Hisp.). If the SNP has been positively associated with LDL-C response with any statin, its best P-value and the reference are listed in columns 10 and 11. If a significant association was found with HDL-C or pharmacokinetics, that is noted in column 10 also.
In addition to carrying out each of the analyses de novo, we can compare our results with those reported previously. This is sometimes not strictly possible because the original studies differed in some details from ours. As shown in Table 3 , only two of the 18 SNPs that were compared to literature results replicated with Po0.05 in our hands. Of these two, only one association was in the same direction as the original data (rs7412 with atorvastatin). While the majority of associations were in the same direction as the original studies, there are a large number with associations in the opposite direction. Those occurring in the same direction may be real but of small magnitude. One published association with rs1045642 in ABC B1 (MDR1) was found in a gender-specific manner. 9 We did not replicate All SNPs noted in Table 1 with a significant association with any outcome are listed with the appropriate phenotype and statin. In the last column, the direction of change in our study relative to the original study is noted.
this finding and our effect was in the opposite direction. However, rs2032582 in ABC B1 was found not to be associated with LDL-C in the previous study, while it was significant in our hands, suggesting larger populations are required to resolve the issue. In addition to genotype, the same associations can be examined as a function of demographic variables including age, gender and ethnicity (Table 4 ). The differences in efficacy within each of these demographic parameters are similar in magnitude to the most significant change observed with any genotype. There are significant differences in LDL-C response between the genders and among age groups and these are identical to those noted previously with lovastatin. 2 
DISCUSSION
Statins have been highly effective agents in lowering LDL-C and preventing cardiovascular morbidity and mortality. While these effects are obvious in most patients, some do not respond as well, spurring efforts to identify markers that may predict such an outcome. However, differences in pharmacokinetics and pharmacodynamics between the various statins make generalizations difficult. Attempts to associate disease outcome as impacted by statins with genotype 3 are particularly challenging because disease event rates are low and affected by many variables. More commonly, lipid responses are examined. 4 Furthermore, while it has been assumed that a significant fraction of statin response variability is genetic, there are no studies directly addressing that issue.
Despite the multitude of papers reporting significant associations between statin response and genotype, very few replication studies have been published. At first glance, this high level of nonreplication may seem surprising, but it is not unlike the situation seen with attempts to replicate genetic associations with other phenotypes. Indeed, analysis of replication rates has revealed that only a small fraction of published associations were replicated. 10 The issues (chance, bias and confounding effects) that can plague association studies and prevent replication have been well described.
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While most of the SNPs we tested were attempts at replications of previous findings, some are not true replications because of differences in study conditions that could potentially affect results. The only statin response association that has been noted repeatedly in the literature is with SNPs rs7412 and rs429358 in apoE. 4 We find an effect of similar magnitude and the same direction as found by others, further confirming the apoE effect.
The lack of replication of other reported associations could be due to many factors. There are differences in the details of the population, the length of treatment, the statin doses and especially the size of the groups examined. While the size of our atorvastatin cohort compares favorably with other large studies, the number of individuals in our cohorts taking the other statins, although larger than most published studies, was too small to ensure that effects seen by others could be replicated. Our time of treatment is sufficient to reach maximal LDL-C lowering but is much shorter than some other studies. All patients in the ACCESS trial were given the lowest starting dose of statin, while other studies have employed a variety of doses.
While pharmacogenomics has been very successful at predicting efficacy or safety for some drugs like warfarin, 12 thiopurines 13 and codeine, 14 none of the associations found here predict atorvastatin LDL-C lowering in a manner sufficient to impact decisions on treatment. Age and gender were equally good at predicting response, although those effects could be due to compliance with the drug regimen 2, 15 rather than intrinsic differences among those groups.
MATERIALS AND METHODS
The ACCESS included 3916 individuals, approximately half of whom (1902) were randomized to atorvastatin and the other half randomized to four other statins (fluvastatin ¼ 477, lovastatin ¼ 476, pravastatin ¼ 462 and simvastatin ¼ 468). 8 Patients were randomized to the highest available starting doses for each of these five statins at the time of study conduct (atorvastatin 10 mg, pravastatin 20 mg, simvastatin 10 mg, lovastatin 20 mg and fluvastatin 20 mg). After 6 weeks of treatment, patients were reevaluated for lipid efficacy and National Cholesterol Education Program (NCEP) ATP II goal achievement. Those achieving goal were maintained on their current statin dose and those not at goal were titrated to the next highest dose. These evaluations were repeated at weeks 12, 18 and 24. Whole blood from participating subjects was obtained with appropriate institutional review and appropriate informed consent documentation that defined the study design and provided an assessment of the risks and benefits associated with study participation. DNA preparation was as described previously. 18 TaqMan assays were obtained from ABI and used for all genotyping except for the CETP SNPs described previously. 16 The genetic effect of each polymorphism was evaluated using ANCOVA for each statin and for each clinical end point. Corresponding baseline was used as a covariate in the ANCOVA model. This allows analysis of genetic effects on statin response without the potential confounding due to factors (including genetic factors) influencing baseline lipid values. Haplotypes were constructed for selected markers with high linkage disequilibrium and the haplotype effect evaluated using ANCOVA. P-values were reported without correction for multiple testing with these data because we want to compare with previous studies, many of which did not use multiple comparison correction. However, the interpretation of any of our significant results should take into consideration the large number of tests performed for 43 markers, five statins and four clinical end points.
